Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

被引：256

作者：

Kumar, S. K. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Kastritis, E. ^{[2
]}

Terpos, E.

Nahi, H. ^{[3
]}

Goldschmidt, H. ^{[4
,5
]}

Hillengass, J. ^{[5
]}

Leleu, X. ^{[6
]}

Beksac, M. ^{[7
]}

Alsina, M. ^{[8
]}

Oriol, A. ^{[9
]}

Cavo, M. ^{[10
]}

Ocio, E. M. ^{[11
]}

Mateos, M. V. ^{[12
]}

O'Donnell, E. K. ^{[13
]}

Vij, R. ^{[14
]}

Lokhorst, H. M. ^{[15
]}

van de Donk, N. W. C. J. ^{[16
]}

Min, C. ^{[17
]}

Mark, T. ^{[18
]}

Turesson, I. ^{[9
]}

Hansson, M. ^{[19
]}

Ludwig, H. ^{[20
]}

Jagannath, S. ^{[21
]}

Delforge, M. ^{[22
]}

Kyriakou, C. ^{[23
]}

Hari, P. ^{[24
]}

Mellqvist, U. ^{[25
]}

Usmani, S. Z. ^{[26
]}

Dytfeld, D. ^{[27
]}

Badros, A. Z. ^{[28
]}

Moreau, P. ^{[29
]}

Kim, K. ^{[30
]}

Otero, P. R. ^{[31
]}

Lee, J. H. ^{[32
]}

Shustik, C. ^{[33
]}

Waller, D. ^{[34
]}

Chng, W. J. ^{[35
]}

Ozaki, S. ^{[36
]}

Lee, J-J ^{[37
]}

de la Rubia, J. ^{[38
]}

Eom, H. S. ^{[39
]}

Rosinol, L. ^{[40
]}

Lahuerta, J. J. ^{[41
]}

Sureda, A. ^{[42
]}

Kim, J. S. ^{[43
]}

Durie, B. G. M. ^{[44
]}

机构：

[1] Mayo Clin Rochester, Dept Hematol, 200 First St South West, Rochester, MN 55905 USA

[2] Univ Athens, Sch Med, Athens, Greece

[3] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Hematol, Stockholm, Sweden

[4] Natl Ctr Tumor Dis Heidelberg, Heidelberg, Germany

[5] Univ Heidelberg Hosp, Dept Med 5, Heidelberg, Germany

[6] CHU Poitiers, Oncol Hematol & Therapie Cellulaire, Poitiers, France

[7] Ankara Univ, Sch Med, Dept Hematol, Ankara, Turkey

[8] H Lee Moffitt Canc Ctr & Res Inst, Hematol Malignancies Program, Tampa, FL USA

[9] Skane Univ Hosp, Dept Hematol, Malmo, Sweden

[10] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[11] Univ Hosp Salamanca, HUS IBSAL, Dept Hematol, Salamanca, Spain

[12] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

[14] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO USA

[15] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

[16] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[17] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hematol, Seoul, South Korea

[18] Weill Cornell Med Coll, New York, NY USA

[19] Lund Univ, Skane Univ Hosp, Dept Hematol, Lund, Sweden

[20] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Ctr Oncol Hematol & Palliat Care, Dept Med, Vienna, Austria

[21] Icahn Sch Med Mt Sinai, Dept Hematol & Med Oncol, New York, NY 10029 USA

[22] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium

[23] North West London NHS Trust, NPH Hosp, Dept Haematol, London, England

[24] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA

[25] Sahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden

[26] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[27] Poznan Univ Med Sci, Dept Hematol & Bone Marrow Transplantat, Poznan, Poland

[28] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[29] Nantes Univ Hosp, Dept Hematol, Nantes, France

[30] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[31] Univ Navarra, Clin Univ Navarra, Pamplona, Spain

[32] Gachon Univ, Gil Med Ctr, Dept Internal Med, Incheon, South Korea

[33] McGill Univ, Hlth Ctr, Div Haematol, Montreal, PQ, Canada

[34] McGill Univ, Montreal, PQ, Canada

[35] Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore

[36] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Japan

[37] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Jeollanamdo, South Korea

[38] Hosp Dr Peset, Valencia, Spain

[39] Natl Canc Ccntcr, Ctr Specif Organs, HematologicOncol Clin, Goyang, South Korea

[40] Hosp Clin iProv, Dept Hematol, Barcelona, Spain

[41] Hosp Univ 12 Octubre, Madrid, Spain

[42] Hosp Duran i Reynals, Inst Catala Oncol, Barcelona, Spain

[43] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea

[44] CedarsSinai Outpatient Canc Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA

来源：

LEUKEMIA | 2017年 / 31卷 / 11期

关键词：

MULTIPLE-MYELOMA; DARATUMUMAB MONOTHERAPY; DEXAMETHASONE; THERAPY; LENALIDOMIDE; BORTEZOMIB; SURVIVAL; PHASE-2; TRIAL;

D O I：

10.1038/leu.2017.138

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T-0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T-0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T-0 was 3.1 years. The median number of lines of therapy before T-0 was 4 (range 3-13). The median overall survival (OS) from T-0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T-0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T-0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.

引用

页码：2443 / 2448

页数：6

共 50 条

[1] Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study
Kumar, Shaji
Dimopoulos, Meletios A.
Kastritis, Efstathios
Terpos, Evangelos
Nahi, Hareth
Goldschmidt, Hartmut
Hillengass, Jens
Leleu, Xavier
Beksac, Meral
Alsina, Melissa
Oriol, Albert
Cavo, Michele
Ocio, Enrique M.
Mateos, Maria Victoria
O'Donnell, Elizabeth K.
Vij, Ravi
Lokhorst, Henk M.
van de Donk, Niels W. C. J.
Min, Chang-Ki
Mark, Tomer
Turesson, Ingemar
Hansson, Markus
Ludwig, Heinz
Jagannath, Sundar
Delforge, Michel
Kyriakou, Charalampia
Hari, Parameswaran
Mellqvist, Ulf-Henrik
Usmani, Saad Z.
Dytfeld, Dominik
Badros, Ashraf Z.
Moreau, Philippe
Kim, Kihyun
Otero, Paula Rodriguez
Lee, Jae Hoon
Shustik, Chaim
Waller, Daniel
Chng, Wee Joo
Ozaki, Shuji
Lee, Je-Jung
de la Rubia, Javier
Eom, Hyeon Seok
Rosinol, Laura
Lahuerta, Juan Jose
Sureda, Anna
Kim, Jin Seok
Durie, Brian G. M.
BLOOD, 2016, 128 (22)
[2] Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S K Kumar
M A Dimopoulos
E Kastritis
E Terpos
H Nahi
H Goldschmidt
J Hillengass
X Leleu
M Beksac
M Alsina
A Oriol
M Cavo
E M Ocio
M V Mateos
E K O'Donnell
R Vij
H M Lokhorst
N W C J van de Donk
C Min
T Mark
I Turesson
M Hansson
H Ludwig
S Jagannath
M Delforge
C Kyriakou
P Hari
U Mellqvist
S Z Usmani
D Dytfeld
A Z Badros
P Moreau
K Kim
P R Otero
J H Lee
C Shustik
D Waller
W J Chng
S Ozaki
J-J Lee
J de la Rubia
H S Eom
L Rosinol
J J Lahuerta
A Sureda
J S Kim
B G M Durie
Leukemia, 2017, 31 : 2443 - 2448
[3] Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
Oostvogels, Rimke
Jak, Margot
Raymakers, Reinier
Mous, Rogier
Minnema, Monique C.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 60 - 67
[4] EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB TREATMENT IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
Oostvogels, R.
Jak, M.
Minnema, M. C.
HAEMATOLOGICA, 2018, 103 : 33 - 33
[5] Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
Yalniz, Fevzi Firat
Akkoc, Nihan
Salihoglu, Ayse
Ar, M. Cem
Ongoren, Seniz
Eskazan, A. Emre
Soysal, Teoman
Aydin, Yildiz
TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (03) : 233 - 238
[6] Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Leleu, Xavier
Martin, Thomas G.
Einsele, Hermann
Lyons, Roger M.
Durie, Brian G. M.
Iskander, Karim S.
Ailawadhi, Sikander
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : 9 - 22
[7] Allogeneic haematopoietic cell transplantation for relapsed or progressive multiple myeloma in the era of immunomodulatory drugs and proteasome inhibitors
Schneidawind, D.
Oehrlein, K.
Weisel, K.
Faul, C.
Kanz, L.
Bethge, W. A.
BONE MARROW TRANSPLANTATION, 2013, 48 : S208 - S208
[8] A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)
Gasparetto, Cristina J.
Lentzsch, Suzanne
Schiller, Gary J.
Bensinger, William
Bahlis, Nizar J.
Sutherland, Heather J.
White, Darrell J.
Sebag, Michael
Kotb, Rami
Venner, Christopher P.
LeBlanc, Richard
Chen, Christine I.
Del Col, Aldo
Kauffman, Michael G.
Shacham, Sharon
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Shah, Jatin
Lipe, Brea C.
BLOOD, 2017, 130
[9] Proteasome inhibitors and immunomodulatory drugs improve survival in relapsed or progressive multiple myeloma after allogeneic hematopoietic cell transplantation
Schneidawind, C.
Duerr-Stoerzer, S.
Faul, C.
Kanz, L.
Weisel, K.
Bethge, W.
Schneidawind, D.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 78 - 78
[10] Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective
Xu, Xu Steven
Yan, Xiaoyu
Puchalski, Thomas
Lonial, Sagar
Lokhorst, Henk M.
Voorhees, Peter M.
Liu, Kevin
Khan, Imran
Jansson, Richard
Ahmadi, Tahamtan
Ruixo, Juan Jose Perez
Zhou, Honghui
Clemens, Pamela L.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →